On November 11, Anke Biotechnology made an announcement regarding its strategic partnership with PersonGen BioTherapeutics. The two entities have entered into an 'Exclusive Agency Framework Agreement for Products Including CD7-CAR-T (PA3-17 Injectable),' which outlines that Anke Biotechnology will act as the sole agent for the PA3-17 injectable product within the Greater China area (comprising Mainland China, Hong Kong, Macau, and Taiwan) once it is introduced to the market. The PA3-17 injectable stands as the globe's inaugural self-derived CAR-T cell therapy targeting CD7, a product independently crafted by PersonGen BioTherapeutics. It is primarily indicated for the management of adult patients with relapsed and refractory CD7-positive malignancies of the hematologic and lymphatic systems. This transaction, being a related-party deal, has received the green light from the company's board of directors, thereby bypassing the necessity for shareholder approval at a general meeting. The objective of this collaboration is to harness the strengths of both firms, diversify Anke Biotechnology's product lineup, and bolster its competitive edge in the innovative pharmaceutical market. Notably, this agreement does not specify a monetary value and is not anticipated to substantially affect the company's immediate operational results.